美国食品药品监督管理局（FDA）高级官员在电话会议中透露，若Moderna公司能够补充完善其流感疫苗的申请材料，该机构将考虑批准该疫苗用于50至65岁人群。这一表态为Moderna拓展其呼吸道疫苗产品线提供了潜在路径。
美国食品药品监督管理局（FDA）高级官员在电话会议中透露，若Moderna公司能够补充完善其流感疫苗的申请材料，该机构将考虑批准该疫苗用于50至65岁人群。这一表态为Moderna拓展其呼吸道疫苗产品线提供了潜在路径。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.